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In reflecting on his extensive career, Ronald T. Borchardt (known to his students, colleagues, friends and family 
members as “Ron”), who is a Distinguished Professor Emeritus at The University of Kansas-Lawrence (KU), has 
told many of his friends and colleagues that he would like for them to look back on his accomplishments and 
know that, in the words of Frank Sinatra, “I did it my way.” As this Dedicated Issue of the Journal of 
Pharmaceutical Sciences reflects on the vast impact Ron has had in several areas of science through his role as 
teacher, mentor, scientist and collaborator, we should also take the time to reflect on the ways in which the 
unique culmination of his life’s choices have led to these contributions. It is a life marked by distinctive and 
singular achievements, by personal and public successes, and an instructive demonstration of one who has 
blazed a trail from humble beginnings in a small town in Central Wisconsin to a very successful career at KU. Ron 
was not born an exception. However, through his hard work, dedication, and the support of his family and 
colleagues, he has become an exception, a “Giant in the Pharmaceutical Sciences”, by doing it his way. 
Early Life and Influences 
Born February 18, 1944, in Wausau, WI, Ron came from humble beginnings.  His mother (Helen) worked in the 
lunchroom at a nearby middle school and his father (Martin) worked in a local factory. Although Ron’s parents 
were working class people, with no more than a grade-school education, they encouraged Ron and his older 
sister Judi (Borchardt) Eckhart to see the value in their education and supported that throughout their lives. 
In what may be a surprise to many of Ron’s former graduate students, postdoctoral fellows, colleagues and 
collaborators, his sister recalls that Ron was never a good student, not in elementary, middle or high school. She 
remembers him as a B-C student whose focus was more on skating at the local ice rink and playing baseball and 
basketball. However, he was not totally unproductive in his early years. Even as a young man, Ron worked hard 
to earn his way: e.g., mowing lawns, shoveling snow, delivering newspapers, and landscaping were among the 
tasks he pursued. It was his summer job at a local factory after graduating from high school that convinced Ron 
that college may be a better option than the backbreaking labor of loading bags of roofing granules onto rail 
cars.  
Though Ron’s focus was often more on sports and work than academics during this period, he learned other 
valuable lessons pursuing these interests, namely, hard work, collegiality, and mentorship.  Though Ron had the 
heart to be a basketball player, he did not have the talent. His high school basketball coach, Marshall Taylor, 
found a way to use Ron’s talents as a manager of the team that won the 1960 Wisconsin state championship. 
“Coach Marsh” led by example, providing a role model for the young men on his team, showing them how to be 
gentlemen.  Ron remembers learning from him how to motivate and to provide a positive impact in the lives of 
young people, a lesson central to his own success as a teacher and mentor at KU. 
So, despite the lack of early academic excellence, Ron always embodied many of the qualities that eventually led 
to his success: an ability to lead others, to control situations, to take in information, and a willingness to work 
hard. 
 




College Life and an Academic Transition 
Even with Coach Marsh’s advice to Ron to pursue his “intellectual talents” over pursuing basketball, Ron still 
took some time to ultimately focus on his academics. A former classmate in the School of Pharmacy at the 
University of Wisconsin-Madison (UW), Judith Thompson (Clinical Associate Professor-Emeritus at UW) recalls 
that Ron probably spent his initial semesters of pre-pharmacy at the University of Wisconsin-Marathon County 
playing too much Bridge and having too much fun outside the classroom. However, after transferring to UW at 
Madison to begin his studies in the School of Pharmacy, Ron’s focus began to change.   
Both Ron’s sister Judi and his classmate in the School of Pharmacy, Judy Thompson, recall his experience in 
organic chemistry at UW as the point at which they witnessed a change in the seriousness with which he took 
his studies. His sister recalls that many of her own friends struggled greatly with organic chemistry. However, 
Ron “breezed” through this course with great joy. She believes organic chemistry turned Ron around 
academically and “opened the door to science” for him. 
Judy Thompson recalls while many of Ron’s classmates in the School of Pharmacy wanted to start small 
businesses as pharmacists when they graduated, Ron was part of a smaller group in the Class of ’67 who focused 
on earning advanced degrees and pursuing careers in academia or industry in the pharmaceutical sciences. 
Because the Pharmacy Program at UW was relatively small, about 100 students in a class, peers became more 
like family in what Judy Thompson calls “an enriched research environment.” Judy says that being in Madison 
really “lit a fire under [Ron].” His focus became tighter, and he became almost like a “heat-seeking missile” with 
respect to learning new things. Furthermore, because he “learns things to a degree that other people do not,” 
he became very successful in his academics endeavors in the School of Pharmacy at UW. 
While Ron’s parents placed great emphasis on the education of their children, they did not have the financial 
means to pay their children’s room and board and tuition at UW. Therefore, Ron had to work each step of the 
way for his undergraduate education. In the School of Pharmacy at UW, Ron found work that would change his 
career trajectory from becoming a pharmacist to becoming a pharmaceutical scientist. Ron’s job involved doing 
all of “the dirty work” in Professor Morris Kupchan’s research laboratory. However, the time that Ron spent 
doing everything from washing dishes, to collecting plants, to extracting potential anticancer drugs from plants, 
became pivotal for his decision to pursue a career in science instead of becoming a pharmacist. After working in 
Professor Kupchan’s research laboratory for approximately 2 years, Ron officially became a member of the 
“Research Team” when Professor Kupchan gave Ron his first research project. This research project ultimately 
gave raise to Ron’s first scientific paper in the Journal of Organic Chemistry.1 
Judy Thompson also reminds us of another aspect of Ron’s early academic life that has advanced throughout his 
career, his collegiality. She notes that while many students who are at the top of the class often feel overly 
competitive, sometimes even sabotaging one another’s success, Ron was “diametrically opposed” to this 
behavior. She remembers that if she ever needed any kind of help, he was there. “It didn’t matter if I scored 
better,” she recalls. “He was the epitome of a colleague.” 




As Ron neared the end of his undergraduate education (B.S. degree in Pharmacy, 1967) at UW, he made a key 
decision to follow the advice of a trusted faculty advisor, which was to contact Professor Edward E. Smissman at 
KU to discuss graduate studies. Professor Smissman, who was a former faculty member at UW, had moved 5 
years earlier to KU to assume a Distinguished Professorship and the Chairmanship of the Department of 
Medicinal Chemistry. 
Ron and his wife, Pamela (Pam), his college sweetheart whom he married in 1966, say they were very impressed 
by the way Professor Smissman and his wife Clare interacted with graduate students and their academic 
colleagues during their very first meeting with the Smissmans in December 1966. Even in their early 
correspondence regarding Ron’s application to Graduate School at KU, one can see Professor Smissman’s 
attention to detail, his thoroughness as well as his kindness and generosity in answering each question that Ron 
posed. Ron ultimately accepted the offer from Kansas and he and Pam moved to Lawrence in June 1967 so Ron 
could start his graduate studies under the direction of Professor Smissman in Medicinal Chemistry at KU. 
Professor Smissman’s influence on Ron cannot be overstated and, in time, Professor Smissman would become 
like a second father to Ron. 
Graduate Education with Professor Edward E. Smissman 
When Ron joined the relatively new research group of Professor Smissman in the Department of Medicinal 
Chemistry at KU in June 1967, he found that Professor Smissman was establishing a very creative program 
exploring a novel concept. The program was based on the realization that some drugs are conformationally 
mobile, i.e., they can with small energetic costs change their molecular shapes among a number of different 
shapes or “conformers”. Such drugs in some cases are known to bind to several different macromolecular 
targets, chiefly proteins, such as enzymes, receptors, etc., to produce a different pharmacological effect for each 
such interaction. The hypothesis held that different conformers of the drug – or the natural effector - might be 
complementary in structure, thus might be a “better fit” for the different targets, and produce in this way a 
distinct effect with each interaction. 
Today such a hypothesis can be and has been explored by determining the structures of the free target protein 
and of the complexes of the target with the natural effector or a synthetic or natural inhibitor. In the late Sixties, 
such approaches lay well beyond the technology of the times. Ron therefore used organic chemistry to design 
and synthesize a series of “conformationally frozen” structures. In these structures, the conformational mobility 
has been blocked so that only one conformer is possible at ordinary temperatures. In Ron’s work, he typically 
made a series of different synthetic compounds into each of which a different conformer was “frozen.” By 
studying the pharmacological and biochemical results of interaction of the target molecule with each of the 
“conformationally frozen” molecules, one discovers which conformer “fits” which target molecule. Today, the 
approach is a general protocol for the application of rational drug design. 
Ron’s work with Professor Smissman produced his doctoral dissertation entitled “A Stereochemical Approach to 
the Adrenergic System“, which was defended in 1970. From his Ph.D. dissertation, Ron and Professor Smissman 
derived three papers, which were published in the Journal of Medicinal Chemistry in 1971. In two of these 
papers,2,3 Ron described the use of a rigid 10-carbon “platform” (trans-decalin) into which he had built the four 




most stable conformers of the neurotransmitters dopamine and nor-epinephrine. These distinct conformers, 
unable to interchange, were exposed to the catabolic enzyme for the natural compounds, catechol-O-
methyltransferase, and each “frozen” conformer had a different rate of metabolism. Still another paper4 with 
Professors Smissman and Barbara Schowen described frozen conformers of acetylcholine, the cholinergic 
neurotransmitter, again with four frozen conformers that reacted at different rates by the acetylcholine 
catabolic enzyme acetylcholinesterase. 
We hope that readers will easily appreciate what a great resonance in the medicinal chemistry world of the late 
Sixties and early Seventies was evoked by the publication of the papers deriving from Ron’s doctoral 
dissertation. We would suggest that, while acknowledging the importance and recognition of the scientific 
findings for Ron’s fledgling career, his personal interactions with Professor Smissman and his observations of the 
attitudes and actions of Professor Smissman during his graduate work may also have contributed much of great 
value for Ron’s subsequent and spectacular career. Those readers familiar with Ron’s attitudes and practices will 
readily agree that Ron seems to have interjected Professor Smissman’s characteristics, or perhaps they were 
already there genetically and just fell in with Professor Smissman’s traits, smoothly and fortunately. Among 
these were: 
Generosity: It has been said of working with Professor Smissman, the only problem was to keep him from giving 
all – the entirety – of the credit for the work to his collaborators. We have never known another scientist so 
creative in attempting to deflect the recognition of his accomplishments onto others. He could make outwitting 
him in these efforts very difficult. 
Transparency and Openness: Professor Smissman took little or no interest in keeping his work secret as he 
shepherded it into publication. His motto seemed to be “tell everybody everything.” This attitude made working 
with him much simpler than it might otherwise have been. 
Broad Scientific Scope: We believe Professor Smissman considered himself an organic chemist with an interest in 
the medicinal-chemical applications of organic chemistry, and he certainly knew and understood everything that 
was happening in organic chemistry. But he also knew and understood essentially everything that was afoot in 
medicinal chemistry, pharmacology, biochemistry, and probably a number of other fields. Whenever a new 
technique was introduced that seemed at least of borderline interest to his work (protein crystallography, 
nuclear magnetic resonance, and computational chemical theory), Professor Smissman leapt on it like the 
outstanding student he once had been. Soon he knew how to make use of it, and was taking steps to fund the 
purchase of the relevant machinery for use at KU and to obtain positions and funding to add new specialists in 
the field to the KU faculty. 
Postdoctoral Study with Drs. Louis A. Cohen and C.R. Creveling at the National Institutes of Health 
As Ron’s graduate studies were finishing up, he arranged (with strenuous support from Professor Smissman) to 
spend a postdoctoral period with Dr. Louis A. Cohen in the Laboratory of Chemistry of the National Institute of 
Arthritis and Metabolic Diseases (NIAMD, a part of the National Institutes of Health, NIH).  Dr. Cohen, a highly 
respected physical-organic chemist, had recently published the initial paper5 in his series “Stereopopulation 




Control”, in which he pointed out that an ingenious arrangement of three methyl groups, the “trimethyl lock,” 
could immobilize certain internal motions of the parent compound, very much related to what Ron had 
accomplished in a different way in the work reported in his doctoral dissertation (1970) and published three 
Journal of Medicinal Chemistry papers2-4 in 1971 and 1972 . Ron held his NIH appointment from 1969 until 1971 
and during that time carried out synthetic and kinetic studies on the “trimethyl-lock” approach that were 
published in five Journal of the American Chemical Society papers6-10 that appeared in 1972 and 1973.  
That Ron’s and Dr. Cohen’s “trimethyl-lock” publications were truly pioneering is beautifully articulated in a 
Perspective article published recently by Michael Levine and Ronald Raines.11  Quoting from the article, Levine 
and Raines say the following about the “trimethyl lock”: “The Trimethyl lock has been employed in chemical, 
biological and pharmacological contexts, providing exceptional stability of conjugates until initiation of a 
designated reaction triggers rapid scission. The trimethyl lock is a readily accessible and highly adaptable 
module. Its conjugation to the amino group of a molecule of interest requires only a condensation reaction, and 
its trigger can be exchanged to alter spatial or temporal aspects of release. The breadth of its demonstrated 
utility has been remarkable.”11 
In the process of his pioneering research on the “trimethyl lock” at the NIH, Ron strengthened his skills in 
measuring and interpreting kinetic data, tools that would later serve him well in his penetration of the fields of 
prodrugs and the stability of peptides and proteins later in his career. 
In his “spare time” at NIH, not commonly thought a concept that applies to a beginning scientific career, Ron 
taught himself protein chemistry and enzymology including enzyme kinetics, and began his work on catechol-O-
methyltransferase, the enzyme used with his decalin derivatives upon which he later achieved international 
fame, including the work with Dr. C.R. (Bob) Creveling that was published in 1973.12  Among the several ways 
that Ron’s professional friendship with Dr. Creveling helped bring him into the neuroscientific community as a 
rising leader was their cooperation in organizing international gatherings and publication of their results. 
Professorial Ranks in Biochemistry 
Having completed his appointment at NIH in 1971, Ron accepted an appointment as assistant professor of 
Biochemistry at KU during the same year. His first four single-author papers13-16 on catechol-O-
methyltransferase, along with a paper17 with Ron’s first graduate student and now-Howard Q. Ferguson 
Distinguished Professor Dhiren Thakker, all appeared in 1973, then another single-author paper on the same 
subject came out in 1974.18  The program on transmethylation was launched. By 1975, Ron was an Established 
Investigator of the American Heart Association and associate professor of Biochemistry at KU, with his 
reputation beyond KU rapidly expanding. He was awarded a full professorship in 1979, with his publication list 
numbering into the seventies and a substantial research group pursuing the transmethylation theme. In 1981 
Ron was recognized for his further achievements by appointment as Solon E. Summerfield Distinguished 
Professor of Biochemistry and Medicinal Chemistry. 
 




Transmethylation and S-Adenosyl-L-Homocysteine Hydrolase  
Ron’s contributions to medicinal chemistry and biochemistry in this area, always supported by thoroughgoing 
basic enzymology and mechanistic biochemistry, have primarily centered around the design, synthesis and 
evaluation of inhibitors of S-adenosylmethionine (AdoMet)-dependent methyltransferases, either directly on 
specific methyltransferases or indirectly through inhibition of adenosyl-homocysteine (AdoHcy) hydrolase.  The 
latter results in elevation of AdoHcy, a common product inhibitor of AdoMet-dependent methyltransferases.   
As a new KU faculty member in 1971, Ron designed inhibitors of catecholamine-O-methyltransferase (COMT), 
establishing structure-activity relationships for certain classes of inhibitors,13-16,19,20 designing affinity labeling 
reagents17,18,21-25 and conducting mechanistic studies.26-28  COMT is responsible for the metabolism of 
neurotransmitters norepinephrine, epinephrine, and dopamine.  Thus inhibition of this enzyme in vivo could 
potentiate neuronal activity by elevating synaptic levels of these neurotransmitters. 
His work in this area quickly expanded into the design and synthesis of inhibitors of other methyltransferases, 
including histamine N-methyltransferase,29-31 indole ethylamine N-methyltransferase,32 t-RNA 
methyltransferases,33 phenylethanolamine N-methyltransferase (PNMT),34-47 protein carboxyl methytransferase 
48-52 and viral mRNA methyltransferases.53-56  The development of PNMT inhibitors and protein carboxyl 
methyltransferase arose from fruitful collaborations with fellow KU faculty members Professors Gary Grunewald 
and Charles O. Rutledge, respectively.   
Further expansion into the area of transmethylation resulted from a focus on broad-spectrum inhibition of 
AdoMet-dependent methyltransferases by AdoHcy analogs, with systematic modifications of the amino acid, 
sugar and base moieties.52,57-64  These broad-spectrum methyltransferase inhibitors were found to also block 
viral mRNA methyltransferases, which are critical for translation of viral proteins in infected cells.  Ron’s 1980 
publication of a Perspective article in the Journal of Medicinal Chemistry on AdoMet-dependent 
methyltransferases as potential therapeutic targets65 established him as a broad thinker in this important area 
of investigation and directly inspired a young graduate student (now-Professor Michael Wolfe) in the 
Department of Medicinal Chemistry at KU to join Ron’s research group to do the research for his Ph.D. 
dissertation. 
Ron’s focus then turned toward indirect inhibition of methyltransferases, particularly as potential broad-
spectrum antiviral agents, through inhibition of AdoHcy hydrolase.  Carbocyclic nucleoside natural products 
aristeromycin and neplanocin A were shown to be potent inhibitors of AdoHcy hydrolase, and the Borchardt 
group carried out molecular dissection and other analog designs of these compounds, establishing structure-
activity relationships, developing chemical tools for mechanistic understanding, and working toward compounds 
that retain the broad-spectrum antiviral properties while minimizing cytotoxic effects.66-111  As one example, 
Ron’s group showed that removal of the 4’-hydroxylmethylene group of neplanocin A retained potent AdoHcy 
hydrolase inhibition and antiviral activity while reducing cytotoxicity, apparently by preventing conversion to the 
5’-triphosphate metabolite, which interacts with other proteins and become incorporated into cellular 
DNA.67,88,112   




The many significant advances that were make over the years by Borchardt’s research group on the design and 
synthesis of very potent and very specific inhibitors of AdoHcy hydrolase inhibitors were made possible through 
long standing and very productive collaborations with Professor Morris J. Robins at Brigham Young University, 
Professor Stanley Wnuk  at Florida International University and Professor Eric DeClerq at the Katholieke 
Universiteit in Leuven, Belgium.   
The Borchardt group also made many seminal contributions to the understanding of the structure and catalytic 
mechanism of AdoHcy hydrolase.113-123 The mechanism by which designed adenosine analogs inactivate AdoHcy 
hydrolase was also elucidated and provided better understanding of the enzyme’s active site and catalytic 
mechanism.112,119,124-133  These advances were made possible through long standing and productive 
collaborations with Ron’s fellow KU faculty members Professors Richard Schowen and Krzysztof Kuczera, and 
Professor P. Lynne Howell at the University of Toronto.  
More recent efforts in Ron’s laboratory have focused on AdoHcy hydrolase from trypanosomes: the cloning and 
characterization of the enzyme allowed comparative biochemistry and the search for selective inhibitors for the 
treatment of deadly infection by this parasite.105,112,119,124-134   Selectivity is currently most likely to emerge not 
from catalytic-site-directed inhibitors, but instead from cofactor-binding-site-directed inhibitors.135-137 
The above provides a brief summary and not an in-depth review of Ron's contributions over the past 45 years to 
the area of AdoMet-dependent transmethylations. For more details about his publications in this area, please 
refer to the following website: http://pharmchem.ku.edu/ronald-borchardt-0. 
The Change to Pharmaceutical Chemistry 
In 1983, Professor Takeru Higuchi put aside the role of Chair of the Department of Pharmaceutical Chemistry at 
KU, continuing his research and entrepreneurial activities as the Regents Distinguished Professor, allowing the 
department to add a new colleague as Chair. Ron was already the Solon E. Summerfield Distinguished Professor 
of Biochemistry and Medicinal Chemistry at KU, and he soon joined the Department of Pharmaceutical 
Chemistry as Chair and Summerfield Professor (1983). Ron has described138 how his move to Pharmaceutical 
Chemistry affected his responsibilities in research and graduate education: “… this career change required me to 
‘phase out’ most of the drug discovery-oriented research projects ongoing in my laboratory in 1983 because 
they had been designed for graduate students and postdoctoral fellows in biochemistry and medicinal 
chemistry. While I was phasing out productive research projects that had contributed significantly to my early 
successes in academia, I had to ‘phase in’ new research projects in the areas of cellular and molecular  
biopharmaceutics and pharmaceutical biotechnology, which I felt were more suited to the interests of graduate 
students and postdoctoral fellows with research interests in pharmaceutical chemistry.” 
Ron has said that “this was a very stimulating time in my life”,139 but also has referred to it as a “great leap of 
faith” in his career.  His approach to drug delivery compared to others working in this field in the mid-to-late 
1980s was unique because he looked at the problems as a medicinal chemist with reduction to the cellular and 
molecular levels.  He realized that one major challenge in medicinal chemistry is how to get a drug to its site of 
action and he wholly exploited this key turning point in his career to expand his personal research interests into 




cellular and molecular biopharmaceutics, an area that he felt would become very important to drug discovery 
scientists as they attempted to “design drugs with ADME (absorption, distribution, metabolism, excretion) in 
mind.”140 
The evolution of Ron’s research interests as a pharmaceutical scientist from the 1980s through the 2010s began 
by developing and validating practical models for biological barriers. He realized that one major challenge in 
medicinal chemistry is how to get a drug to its site of action and he felt that such models would become very 
important to drug discovery scientists as they simultaneously optimized the pharmacological and drug-like 
properties of lead molecules through rational drug design strategies or by fixing their poor drug-like properties 
using prodrug design strategies. Consequently, the Borchardt laboratory became users of these cell culture 
models, as well as traditional in situ models, to elucidate how the structure of peptides and peptidomimetics 
affected their permeation across the intestinal mucosa and the blood-brain barrier (BBB) and to evaluate novel 
prodrug strategies for delivering therapeutic peptides orally and into the brain. Such cell-based systems are now 
used routinely in the pharmaceutical industry to aide design of safer and more efficacious drugs. 
Practical Models for Biological Barriers to Drug Delivery 
A major output from Ron’s research group was the development and use of cell culture models of the intestinal 
mucosa and the BBB. In a 1997 interview,139 Ron said that he is “most proud of our accomplishments in 
biopharmaceutics, particularly in the area of cell culture systems and their use to study drug transport.” Ron 
realized that the pharmaceutical industry needed models to study these two very important barriers that were 
major hurdles in the delivery and development of efficacious drugs. In the early 1980s, barrier function was 
studied in animal models or isolated tissues, but these models were expensive, time consuming, and had 
drawbacks.141,142  Ron “envisioned these in vitro cell culture models as having significant potential for estimating 
the oral absorption and the brain permeation of drug candidates, thus reducing the need to conduct expensive 
and sometime controversial animal experiments”. 
Ron’s new interests in applying cell culture models to the study of drug transport began in early 1984 when 
now-Dean and Professor Audus joined his research group as a postdoctoral fellow. Ron had developed a 
particular interest in growing cells on permeable supports that would allow investigation of transcellular 
transport of drugs. This interest was further fueled by discussions with research groups at The Upjohn Company 
(Kalamazoo, MI) and INTERx Research Corporation-Merck Sharp and Dohme Research Laboratories (Lawrence, 
KS) that had similar interests and the financial resources to help pursue specific projects in Ron’s laboratory. The 
first system that the Borchardt group explored was a cell culture model for the BBB. After initial attempts to 
establish cultures of brain microvessel endothelial cells proved to be a challenge, Ron arranged a meeting with 
Professor William “Bill” Pardridge from the UCLA School of Medicine in October of 1984. Professor Pardridge 
was one of a few prominent researchers in the area of drug delivery through the BBB at the time and he was in 
Lawrence (KS) to participate in a drug delivery conference dedicated to Professor Takeru Higuchi.  Although a 
few examples of isolated brain microvessel endothelial cells and cultures of those cells appeared in the literature 
prior to 1984, the leads and contacts Professor Pardridge provided in the meeting were key in the eventual 
development of a primary cell culture system derived from bovine brain tissue.143  Primary cultures of bovine 
brain microvessel endothelial cells (BBMEC) could be grown in culture dishes or on semi-permeable supports 




and were exploited to understand nutrient and drug transport,144-149 metabolism mechanisms,150-154 and 
receptor expression.155-157  These validating studies led to the use of this BBMEC model for subsequent 
mechanistic and structure-property relationship studies of drug transport across the BBB (see sections on 
Prodrug Strategies for Therapeutic Peptides and Characterization of Drug-like Properties). The interest in this 
work also prompted at least six review articles summarizing their accomplishments from 1987 to the last one in 
1998.158 
When Dr. Ismael J. Hidalgo joined Ron’s research group in 1986 as a postdoctoral fellow, they pursued the 
elusive idea of developing a cell culture model of the intestinal mucosa. The “back story” for this pioneering 
work has been told by Ron in 2011.138  Dr. Hidalgo identified several papers published in the 1970s and early 
1980s by Professor Alain Zweibaum and colleagues at INSERM (Villejuif, France) describing the human colon 
adenocarcinoma Caco-2 cell line that spontaneously differentiates into polarized, confluent cell monolayers with 
tight junctions in approximately 15–20 days.159 When grown on a filter support, these cell monolayers display 
morphological, functional and enzymatic characteristics typifying the human intestinal mucosa.160  As with the 
BBMEC model, validating studies on transport mechanisms were also conducted.  For example, Dr. Hidalgo 
established that Caco-2 cell monolayers actively transported the bile acid taurocholate.161  Then, Ron’s 
laboratory and collaborators at The Upjohn Company (Kalamazoo, MI) used the Caco-2 cell model to evaluate 
whether the bile acid transporter can enhance the ability of renin-inhibitory peptides to penetrate the intestinal 
mucosa by synthesizing and testing peptide-cholic acid conjugates.162  A similar “one-two punch” was used by 
exploiting the functional expression of a biotin (vitamin H) transporter, now known to be the sodium-dependent 
multivitamin transporter (SMVT or SLC5A6), in Caco-2 cells and the intestine to assess whether oral absorption 
of peptidic HIV-1 protease inhibitors could be enhanced through biotin-peptide conjugation.163,164 
Such studies led to many subsequent applications of the Caco-2 cell and BBMEC models in Ron’s laboratory to 
elucidate the structural features of peptides and peptidomimetics influencing their ability to cross cell 
membranes. The cell-based systems also have been used in Ron’s laboratory to develop innovative prodrug 
strategies that result in enhanced cell membrane permeation of peptides with a particular focus on the 
importance of conformation of cyclic prodrugs of peptides on membrane permeation as discussed in Prodrug 
Strategies for Therapeutic Peptides and Characterization of Drug-like Properties. 
These cell culture models have opened new paths of research and have had enormous impact on several areas 
within pharmaceutical sciences, more specifically within drug delivery research and drug discovery. The Caco-2 
model is presently being used worldwide as a screening tool during drug discovery to compare putative drug 
candidates for their absorption potential and to eliminate drug candidates that are likely to fail in later 
development due to poor biopharmaceutical properties. These cell monolayer models therefore have become a 
very important decision making tool in the pharmaceutical industry resulting in improved accuracy in prioritizing 
new compounds at the discovery stage. Besides the intrinsic originality and quality of these studies, the 
contributions from Ron’s laboratory literally created a new approach to drug discovery development where 
pharmaceutical scientists were willing to use cell culture models to study drug transport across biological 
barriers instead of animal, tissue, and isolated cell models. As a consequence of their collective Caco-2 work and 
its impact, Ron and Dr. Hidalgo shared a 2007 award from the Society for Biomolecular Sciences Polypops 
Foundation. 




This is one area of Ron’s research that fueled and benefitted from his intense dedication to education and 
shared learning. In addition to launching two short courses on cell lines and tissue culture in pharmaceutical 
research and development at KU in response to the outpouring of requests for acquiring these models, Ron was 
co-editor or series editor for two books on this topic.165,166  He also organized and participated in three American 
Association of Pharmaceutical Scientists (AAPS)-sponsored short courses on cell culture systems in 1994, 1996, 
and 1998. 
The above provides a brief summary and not an in-depth review of Ron's contributions over the past 32 years to 
the area of cell-based models for biological barriers to drug delivery. For more details about his publications in 
this area, please refer to the following website: http://pharmchem.ku.edu/ronald-borchardt-0. 
Protein and Peptide Stability 
When Ron was selected as Chairman of the Department of Pharmaceutical Chemistry at KU in 1983, he seized 
that opportunity to lead the department into the area of pharmaceutical biotechnology. That seminal decision 
lead to the establishment of a course in the department’s graduate program which was focused on 
pharmaceutical biotechnology and also in the recruitment of new faculty members with research interests 
focused in this emerging area. Over the years, Ron’s decision has radically transformed KU’s Department of 
Pharmaceutical Chemistry, where today more than 70% of the faculty members perform research in this area, 
including the design, formulation, stabilization and analysis of protein pharmaceuticals and vaccines.  
Instrumental to the evolution of pharmaceutical biotechnology education and research at KU was securing a NIH 
Training Grant in this area, which Ron successfully did in 1989. That Training Grant still exists in the department 
today. In fact it was recently renewed, which means it will continue to support pharmaceutical biotechnology 
graduate students at least until 2019. Thirty years of continuous support for this type of NIH Training Grant is 
very unusual and a significant accomplishment for the faculty members in KU’s Department of Pharmaceutical 
Chemistry. An important aspect of this Training Grant is the requirement for graduate student trainees to accept 
3-6 month industrial internships in biotechnology companies. These internships soon became an important part 
of training not only for the graduate students being supported by the Training Grant, but also for most of the 
graduate students in KU’s Department of Pharmaceutical Chemistry. These industrial internships have opened 
the door to multiple collaborations between students, faculty members and industrial scientists and to future 
career paths for the department’s graduate students.  
With respect to Ron’s research, his first publication in the area of pharmaceutical biotechnology dates back to 
1989 when he authored a review paper with Dr. M.C. Manning entitled “Stability of Protein Pharmaceuticals”.167  
The importance of this paper in the field is evident from the fact that it has been cited over 700 times as of 
August 2015.  
The research interest of the Borchardt laboratory in peptide and protein stability began to increase in the early 
1990s. The first research papers in this field from his laboratory, which were published in 1990, focused on 
deamidation and on the influence of peptide sequence on the deamidation of asparagine residues.168,169  These 
papers became the first in a series of important papers addressing the kinetics of hydrolytic degradation 




reactions in solution,170 in polymers171 and in the solid state,172 and the effects of sequence,170 secondary 
structure173 and formulation variables174 on these kinetics. Rate constants derived in these studies continue to 
guide researchers in their quest to identify hotspots for asparagine deamidation in therapeutic peptides and 
proteins. 
In 1991, Ron expanded his research interests to cover mechanisms of peptide and protein oxidation, and a series 
of papers documented his prolific efforts in this area.175,176 It was around this time, that a group of international 
students and postdocs in his laboratory decided to use the Thanksgiving Break for a road trip to New Orleans. 
This group included about half of the biotechnology researchers in Ron’s laboratory at that time. Realizing the 
inexperience of the foreigners, and the potential dangers of a big American city, Ron not only rescheduled a 
group meeting originally planned for the day after Thanksgiving (!), but also quickly changed the topic of the 
meeting from a discussion of research progress to general travel advice and rules of conduct, especially on 
Bourbon Street. Everybody made it back safely and biotechnology research continued to evolve in the Borchardt 
research group.  
In the pursuit of his research interests, Ron had the foresight to assemble teams of various faculty members, 
graduate students and postdoctoral fellows with complementary expertise to drive projects in areas like peptide 
and protein stability. Besides Ron, the other KU faculty members involved in these pharmaceutical 
biotechnology projects were Professors Richard Schowen, Christian Schöneich and Elizabeth Topp (now at 
Purdue University). Such collaborations resulted in a multi-year project on hydrolytic degradation pathways of 
peptides and proteins in polymer matrices and the solid state. In this project, the precise mechanism of 
racemization during asparagine deamidation was elucidated.177 The collaboration of these faculty members, 
graduate students and postdoctoral fellows not only ensured competitive NIH funding, but also created a 
climate of intense exchange and development of ideas, which paved the way for many successful careers of 
young researchers and faculty members. 
Mentoring young researchers was close to Ron’s heart, and key to the success of the Department of 
Pharmaceutical Chemistry during his tenure as Chairman. The countless opportunities he outlined before his 
colleagues, e.g., scientific collaborations, new research areas, ideas for potential courses, short courses, and 
scientific inquiry, provided and continue to provide a fertile ground for scientific discovery in KU’s Department of 
Pharmaceutical Chemistry. For example, today the Department of Pharmaceutical Chemistry is home to the 
Macromolecule and Vaccine Stabilization Center and the Kansas Vaccine Institute. The existence of these two 
Centers is a logical extension of what began with Ron’s vision to establish pharmaceutical biotechnology in the 
Department of Pharmaceutical Chemistry at KU. 
The above provides a brief summary and not an in-depth review of Ron's contributions over the past 32 years to 
the area of protein and peptide stability. For more details about his publications in this area, please refer to the 
following website: http://pharmchem.ku.edu/ronald-borchardt-0. 
Characterization of Drug-like Properties  




When Ron took over the responsibility as the Chair of the Department of Pharmaceutical Chemistry in 1983, he 
made a strategic decision to pivot his training and experience as well as his instincts as a medicinal chemist to 
address one of the most relevant questions in drug discovery and development of the time – “what does it take 
for a molecule with potent and selective biological activity to become a successful drug?” Therein lies the genius 
of this incredible scientist/teacher/mentor/faculty member/Department Chair! Too many times, scientists let 
their training and their strength in a specific area of science become their biggest limitation, and see the world 
through the glasses of their training.  Ron took a very different approach. An approach that has been a hallmark 
of his long and illustrious career, and that is to step back from time to time, and reflect on the most relevant 
questions that are staring us in the face, and then attack the problem by applying one’s own training and by 
bringing in new talents from different disciplines. The quote “For example, this career change… in 
pharmaceutical chemistry.” (see The Change to Pharmaceutical Chemistry section) from Ron’s commentary138 
expresses well this philosophy in his own words. Perhaps he does not realize this, but this approach of Ron’s has 
been an inspiration to many of his students and junior colleagues, represented by some of the co-authors of this 
commentary, who have watched him from a distance as they are pursuing their careers in academia or industry 
and as they have made their own career transitions.  
Coming back to the question Ron asked about the properties of a molecule that would make it a successful drug, 
Ron turned his attention to the two barriers that routinely prevent the drugs to reach where they are supposed 
to reach to achieve their therapeutic potential, i.e., intestinal mucosa that prevents orally administered drugs to 
reach systemic circulation, and BBB that prevents the drug designed to treat central nervous system diseases 
from reaching the brain tissue.  He recognized the importance of designing drugs and formulations that can 
enable the drug to navigate across these barriers successfully.  Ron’s training and instincts as a medicinal 
chemist led him to look for simple in vitro tools to screen for compounds that can or cannot cross these barriers.  
He recognized that traditional in vivo approaches using animal models would be too slow for screening and too 
complex to understand the problems associated with poorly performing compounds, and proceeded to develop 
cell culture-based models of the BBB and intestinal mucosa by bringing in postdoctoral fellows as described in 
the Practical Models for Biological Barriers to Drug Delivery section.  Using a typical “Borchardt approach”, Ron 
recognized the potential importance of peptides and peptide-like compounds as an attractive chemical space for 
discovering new drug candidates, but also recognized the liabilities of these molecules with respect to stability 
and permeability across biological barriers such as BBB and intestinal mucosa.  Hence, Ron undertook a 
significant effort in elucidating the physicochemical properties of peptides that affect their stability and 
permeability, and therefore their ability to be useful drugs.  Ron’s work in these areas is described below and in 
the Prodrug Strategies for Therapeutic Peptides section. 
The work done in Ron’s laboratory starting in the mid-1990s focused on elucidating the “structure-transport 
relationships” for peptides and peptide-like compounds (also referred to as peptidomimetics).  The model 
biological model systems used in these studies included cell culture models and in situ perfusion models of the 
intestinal mucosa and the BBB (see the Practical Models for Biological Barriers to Drug Delivery section). The 
physicochemical and biological properties studied by Ron’s group over about a 10 year period included the 
following: (i) the effect of beta-turn structures on passive diffusion of peptides and peptidomimetics through the 
intestinal mucosa and the BBB;178-180  (ii) the effect of hydrogen bonding potential on passive diffusion and 
passive diffusion modified by efflux transporters of peptides and peptidomimetics through the intestinal mucosa 




and the BBB;181-186  (iii) the effect of structural features of peptides and peptidomimetics on substrate activity for 
the peptide transporter in the intestinal mucosa;187-191 and (iv) the effect of structural features, particularly size 
and charge, of peptides and peptidomimetics on their permeation via the paracellular route across the intestinal 
mucosa.192 The results of these studies are described in several review articles.193-196  The advances made by 
Ron’s group in this area were made possible through longstanding and productive collaborations with his fellow 
KU faculty members including Professors Teruna Siahaan, Jeffrey Aube (now at the University of North Carolina) 
and David Vander Velde (now at CalTech), as well as Professors Ralph Hirschman and Amos B. Smith at the 
University of Pennsylvania, Drs. Philip Burton and Norman Ho at the Upjohn Company and Drs. Philip L. Smith 
and Chao-Pin Lee at SmithKline Beecham Pharmaceuticals.   
Ron’s work on “identifying, screening for, and improving drug-like properties” since the 1980s has had an 
enormous impact throughout the pharmaceutical and biotechnology industry.  Arguably, even bigger impact on 
the industry and science of drug development in the area of “instilling drug-like property into drug candidates” 
has been through Ron’s contributions as an educator.  Ron has been a “preacher” to the “drug discovery and 
development community”, and the central message of his “sermon” is “drug candidates are not high-affinity 
ligands, they must have drug-like properties”. Ron has relentlessly conveyed the message that one must instill 
“drug-like properties” in drug candidates, and many of the authors of this commentary have either witnessed 
Ron “preaching” this “sermon” or have joined him at his invitation to help him in this mission. Ron’s enormous 
work and equally enormous impact in this area is reflected in a large number of books that he has edited or co-
edited,197-201 and courses or workshops (sponsored by professional associations (e.g., AAPS), universities (e.g., 
Drew University), student-centered conferences (e.g., Globalization of Pharmaceutics Education Network), and 
pharmaceutical/biotechnology companies (e.g., on-site courses offered in the U.S.A. and Europe)) that he has 
organized, co-organized, and taught.  The courses organized by Ron and sponsored by Drew University that 
focused on “designing drugs with optimal in vivo activity after oral administration” and “designing drugs with 
optimal blood-brain barrier permeability” for nearly 10 successive years were so popular among pharmaceutical 
scientists, managers, and senior leaders that many applicants had to be turned down each year. Many of the 
authors of this commentary were invited by Ron to participate in these short courses, specifically, the Drew 
University short courses, and have witnessed the enormous impact Ron has had through these courses by 
training thousands of pharmaceutical scientists in the science and art of designing and developing drugs with 
optimum pharmaceutical properties. One of the authors of this commentary (Professor Thakker) has had the 
privilege to not only participate in many of the short courses and workshops organized by Ron, but also travel 
with him (and Professors Val Stella and Kim Brouwer) over 30 times to various companies (and groups of 
companies) across the U.S.A. and in Europe to teach the course on “designing drugs with optimal in vivo activity 
after oral administration” over a 10-year period.  During those trips, one witnessed the masterful teacher at 
work.  Ron showed his mastery at engaging his audience with humor, story-telling, artfully created visuals, and 
straight-talk.  Those trips taught so much to his “touring team members” and will always have a special place in 
the hearts and minds of Ron’s traveling teammates.   
In addition to teaching the science of optimizing drug-like properties, Ron took the opportunity to teach his 
audiences the value of communication and teamwork across various drug discovery/development disciplines. In 
his inimitable style, Ron would chide the company scientists in the audience by telling them that often he ended 
up introducing the scientists in the medicinal chemistry or biology department of the company to their 




colleagues in the formulation or drug metabolism/pharmacokinetics department.  Ron would show slides 
depicting “silos” within discovery research, preclinical development, and clinical development; he would also 
show slides that depicted lack of interactive feedback between these silos, and label those as “Recipe for 
Failure!!!”.  He would have slides with a title like “Because of a Lack of Input from Development Scientists, 
Discovery Scientists Tended to Fall into “The High Affinity Trap”, followed by slides showing Drug Discovery 
Paradigm of the Future.  Unquestionably, through these teachings Ron has had an impact in drug 
discovery/development that is quite difficult to measure. All one can say is “the impact has been truly 
transformative”. 
The above provides a brief summary and not an in-depth review of Ron's contributions over the past 25 years to 
the area of characterization of drug-Like properties.  For more details about his publications in this area, please 
refer to the following website: http://pharmchem.ku.edu/ronald-borchardt-0. 
Prodrug Strategies for Therapeutic Peptides 
Ron’s research interests concerning prodrugs have been focused on improving the delivery of drug molecules 
across biological barriers such as the intestinal mucosa and the BBB.202 A prodrug is a conjugate of a promoiety 
to a functional group of the drug via a cleavable bond (e.g., ester, amide). The formation of a prodrug transiently 
changes the physicochemical properties of the drug for improving solubility and/or cell membrane permeation 
through the intestinal mucosa and/or BBB. The idea is that the bond between the drug and promoiety can be 
cleaved by enzymatic and/or chemical reaction(s) to convert the prodrug to the drug after delivery to the site of 
action. As his work in other fields, Ron’s research in the prodrug area is a beautiful reflection of his ability to go 
across disciplinary boundaries in finding solutions to contemporary pharmaceutical problems.    
After moving to KU to become a faculty member, Ron and his graduate student Kent Amsberry took advantage 
of Ron’s findings as a postdoctoral fellow at the NIH related to the lactonization rate acceleration by a “trimethyl 
lock”6-10 and applied them to prodrug design. Specifically, they compared prodrugs of p-methoxyphenyl amine, 
model compound, using 3-(2'-(benzyloxy)-4',6'-dimethylphenyl)-3,3-dimethylpropionic acid (3-BDPA) and 2'-
hydroxyhydrocinnamic acid (2’-HHCA)  promoieties to prove that this “trimethyl lock” group affected the rate of 
release of the amine. It was shown that the rate of p-methoxyphenyl amine release from the 3-BDPA promoiety 
having the “trimethyl lock” was 25,000 times faster than from the parent 2'-HHCA promoiety without the 
“trimethyl lock”.203  Ron and colleagues then extended the “trimethyl lock” concept to a quinone promoiety, 
which is a redox-sensitive promoiety for lactonization, to convert the amine prodrugs to the drug.204 
In another example of bringing in tools available in related disciplines to solve pharmaceutical problems, Ron’ 
research group worked on understanding the effect that the conformation of delta-sleep-inducing peptide 
(DSIP) had on its ability to cross the BBB.205  To accomplish this goal, they studied the conformation of DSIP using 
various biophysical methods (i.e., NMR, CD, FTIR, and fluorescence) and found that DSIP had a propensity to 
form type-I beta-turns at residues 2–5 and 6–9, suggesting that the conformation of DSIP could contribute to 
BBB permeation.205  Using a conformationally-stable hexapeptide fragment of DSIP, Ron’s group systematically 
studied the effect of conformation on membrane permeation using linear and cyclic peptides.178  They 
discovered that the cyclic hexapeptide had a faster cell membrane permeation rate than the linear hexapeptide; 




furthermore, the cyclic hexapeptide had a more well-defined structure than the linear peptides as determined 
by various biophysical methods (i.e., NMR, molecular dynamics simulations).178  This study suggested that 
stabilization of peptide conformation by forming cyclic peptides could enhance peptide transport through cell 
membranes.  
Although cyclic peptides have better cell membrane permeation than linear peptides, the formation of a cyclic 
peptide from a linear peptide can alter the biological activity of the linear peptide. Therefore, there was a need 
to find a way to form cyclic peptides temporarily.  To solve this problem, the Borchardt group investigated the 
formation of cyclic peptide prodrugs that would temporarily stabilize the peptide conformation and, at the same 
time, change the physicochemical properties of the peptide to favor cell membrane permeation.202  The idea 
was that the cyclic peptide prodrugs could be converted to parent peptides after the transport process. Ron and 
his collaborators developed and studied the cyclic prodrugs of opioid peptides using different promoieties, 
including “trimethyl lock” phenyl propionic acid, coumarinic acid, acyloxyalkoxy, and oxymethyl-modified 
coumarinic acid (OMCA) promoieties.202,206,207  The cyclic peptide prodrugs were constructed by linking the 
peptide N-terminus to the promoiety via an amide bond and the C-terminus to the promoiety via an ester bond. 
The subsequent improvement in membrane permeability is due to the stabilized conformation of cyclic peptide 
prodrug that reduces hydrogen bonding potential, increases hydrophobicity, reduces charges, and increases 
metabolic stability against exo- and endopeptidases. The cyclic peptide prodrugs can also be converted to the 
parent peptides by enzymatic reaction followed by rapid chemical reaction. 
In the prodrug area, the Borchardt group has had a major impact on improving oral absorption and brain 
delivery of small molecules, including peptides, and peptidomimetics and achieving a good understanding of 
factors important to controlling delivery properties.202 Reflected in these advances was also Ron’s ability to build 
teams of collaborators from related disciplines. Especially worth mentioning was his long-standing and 
productive collaborations with Ron’s KU faculty colleagues Professor Teruna Siahaan and David Vander Velde 
(now at CalTech).  Ron’s former postdoctoral fellow, Professor Binghe Wang of Georgia State University, also 
continued his collaboration in the prodrug area with Ron for a number of years after leaving his laboratory. 
Other investigators have also applied the “trimethyl lock” promoiety and similar concepts to make prodrugs of 
anticancer agents (e.g., daunorubicin, ganciclovir, taxol) as well as fluorogenic probes.11 Ron’s group and others 
have utilized the cyclic peptide prodrug concept to improve oral delivery of antithrombic agents (RGD peptides 
and peptidomimetics).208-212 Finally, the “trimethyl lock” concept has also been utilized in cleavable linkers or 
protecting groups in the solid-phase synthesis of peptides and oligonucleotides.11 
The above provides a brief summary and not an in-depth review of Ron's contributions over the past 25 years to 
the area of prodrugs of therapeutic peptides.  For more details about his publications in this area, please refer to 
the following website: http://pharmchem.ku.edu/ronald-borchardt-0. 
National and International Recognition for Research 
The sheer number and quality of Ron’s contributions are a testament to his deserving accolades. Over his 50-
year career, Ron has published approximately 500 scientific papers in peer-reviewed journals, has authored or 
co-authored approximately 460 posters and podium presentations at national and international meetings, and 




has presented approximately 180 invited talks of which about 40% were international. Ron’s colleagues, both at 
home in the USA and throughout the world have frequently accorded him appreciative recognition for the 
quality and quantity of his research work. Most recently, in 2008, the Academy of Pharmaceutical Sciences and 
Technology-Japan (APSTJ) appointed him an International Fellow for his lifetime contributions to the 
pharmaceutical sciences. He was inducted into the American Chemical Society-Medicinal Chemistry Division Hall 
of Fame in 2007 in recognition of his lifetime contributions to the field of medicinal chemistry. In the same year, 
Ron and Dr. Ismael Hidalgo shared the Society for Biomolecular Sciences Polypops Foundation Award for the 
seminal discovery and development of Caco-2 cells as a model for the intestinal mucosa. Ron was the recipient 
in 2003 of the Smissman-Bristol-Myers Squibb Award in Medicinal Chemistry, given by the Medicinal Chemistry 
Division of the American Chemical Society (ACS) for his research contributions to the field of medicinal 
chemistry. Also in 2003, the American Pharmacists Association chose Ron to receive its most prestigious 
scientific award, the Takeru Higuchi Research Prize, for his lifetime research and educational contributions to 
the pharmaceutical sciences.  The same association had in 2001 given Ron its Research Achievement Award in 
the Pharmaceutical Sciences for research contributions to that field. Ron’s lifetime research and educational 
contributions to the pharmaceutical sciences earned him in 1999 the most prestigious award given by the 
International Pharmaceutical Federation, the Host-Madsen Medal, presented by its Board of Pharmaceutical 
Sciences. The Volwiler Research Achievement Award, the most prestigious award of the American Association of 
Colleges of Pharmacy (AACP), went to Ron in 1998 for his lifetime research and educational contributions to the 
pharmaceutical sciences.  Ron’s research contributions to the field of biotechnology brought him in 1997 the 
Paul Dawson Biotechnology Award from the AACP. In the same year, the AAPS selected Ron, in recognition of his 
lifetime research and educational contributions to the pharmaceutical sciences, to receive the most prestigious 
award given by AAPS, the Distinguished Pharmaceutical Scientist Award. Ron was elected Fellow of the 
American Association for the Advancement of Science (AAAS) in 1995. In 1994 Ron’s research contributions to 
the field of medicinal chemistry brought him the Research Achievement Award in Medicinal Chemistry and 
Natural Products Chemistry from the AAPS. The same body, AAPS, had given Ron the Research Achievement 
Award in Biotechnology in 1993 for research contributions to the field of biotechnology. Also in 1993 Ron was 
the recipient of the Takeru and Aya Higuchi Memorial Award of the APSTJ.  This award was given to him for his 
research contributions to the field of pharmaceutical chemistry.  It is the most prestigious award given by APSTJ 
in the field of pharmaceutical chemistry. Ron was elected Fellow of the AAPS (1988). Ron was the 1983 winner 
of the Dolph Simons Sr. Award for research achievement in the biomedical sciences. For his contributions to 
biochemistry, Ron was given the Sato Memorial International Award from the Pharmaceutical Society of Japan in 
1981. 
 In addition to these prizes and awards, Ron has received honorary doctorates from the Danish University of 
Pharmaceutical Sciences, Copenhagen, Denmark (2002), the Katholieke Universiteit, Leuven, Belgium (2004) and 
from Uppsala University, Uppsala, Sweden (2006). 
Mentor of Graduate Students and Postdoctoral Fellows  
Ron’s research groups were vital, exciting to work in, intellectually nurturing, and professionally productive. 
Over the years, 19 Master’s students, 62 Ph.D. students, 63 postdoctoral students, and 24 visiting scientists from 
around the world worked in Ron's laboratory. These individuals were associated with the Departments of 




Biochemistry, Medicinal Chemistry or Pharmaceutical Chemistry at KU, or with the Danish University of 
Pharmaceutical Sciences, Copenhagen, Denmark or Uppsala University in Uppsala, Sweden. 
Ron made use of an exceedingly effective means of directing and advising doctoral research students, a means 
that left each student with an approach to research that was optimal for time and resource management, for 
exercising good judgment in choosing among alternative research pathways, and which assured that important 
matters were not neglected or forgotten in assembling the experimental support for papers in preparation.    
When new students joined the group, they and Ron in private conversation worked out a plan for the doctoral 
dissertation, i.e., the questions to be answered and at least a first few steps in the direction the experimentation 
should take. The students then went off to read and begin to develop what will in the end form the table of 
contents of the doctoral dissertation. At group meetings, they would soon present a draft table of contents in 
which they will have divided the overall problem into a strategic collection of parts, each commonly forming a 
coherent whole that will become a chapter in the dissertation, and that appears to represent an orderly 
approach to the overall problem. Good feedback was always offered by attendees at every group meeting; Ron 
continuously modeled how to correct or criticize in a collegial and good-humored way, so that a tone of 
friendliness and helpfulness prevailed. There was also a deliberate tone of egalitarianism: Ron never spoke to 
senior people with any greater (or lesser) courtesy or respect than he used with the newest students. 
The same respect, courtesy, and collegiality prevailed in the laboratory where the students and postdoctoral 
coworkers pursued the experimental and sometimes computational aspects of the work. They all understood 
and  appreciated how these qualities (which one would suspect in many cases were aspects of Professor 
Smissman’s practices that Ron had explicitly or implicitly taken over into his own approaches) create a highly 
productive group with members who lead a pleasant daily life and form in many cases lifelong friendships. 
As students progressed through the graduate program and moved toward “writing up” and receiving their 
degrees, their draft table of contents became an invaluable tool for time and resource management, and 
offered many opportunities for instilling and elaborating a culture of timely publication in the correct journals.  It 
is a vital educational necessity to bring maturing young scientists into this culture and to equip them with 
decision - making tools that enable a thoughtful assessment of their research and what to do about it at any 
arbitrary time, of what direction to go next, how to finish up a paper for publication with no dangling 
unanswered questions, and many other potential pitfalls. 
In addition to the above, Ron always encouraged all coworkers at every level to seize all opportunities to present 
their scientific work, either orally or in print, thus simultaneously “spreading the word” about what they had 
found, and also honing their skills in scientific communication. Although Ron’s travel schedule was truly hard to 
believe, in terms of the frequency of travel and the intensity of the work he managed to force into every spare 
second of a trip, the fact was that no coworker of his ever lacked for his dedicated and thoughtful attention at 
any point – while working on the draft of a manuscript, preparing an oral presentation or a poster presentation. 
For graduate students, there was no choice: Ron saw to it that he heard rehearsals of talks, went over 
presentation slides or went over posters, provided detailed critiques, and was there to hear or go over the 
corrected version. For postdocs or colleagues, he was available if and as desired. 




Mentor of Faculty Colleagues 
Ron has always taken an interest in the academic fortunes of his colleagues, and has given valuable advice and 
encouragement. If their later success is any measure of his influence, it has certainly been good.  
 Professor Kenneth Audus, a postdoctoral fellow with Ron who was critical in the development of a cell-
culture model for the BBB, joined the faculty of the Department of Pharmaceutical Chemistry at KU in 1986 
and rose through the academic ranks to become a Full Professor in 1996 and then Chair of the Department 
in 1998. Ken is also a Professor of Molecular & Integrative Physiology at KU Medical Center in Kansas City 
and became Dean of the School of Pharmacy in April of 2004. He is a Fellow of AAPS and he has been 
recognized as an AACP Teacher of the Year and for Excellence in Undergraduate Teaching of Pharmaceutical 
Chemistry at KU. 
 Professor Christian Schöneich, while a postdoctoral coworker of Professor George Wilson and Ron, began his 
studies of oxidation reactions in proteins and peptides. As a young faculty member whose own graduate 
education had been completed in the rather different German academic system, Christian had to make 
some adaptations to the American and indeed KU systems, and Ron surely helped. Christian is now the Chair 
of the Department of Pharmaceutical Chemistry at KU and holds the Takeru Higuchi Distinguished 
Professorship of Bioanalytical Chemistry. 
 Professor Teruna Siahaan took bachelor’s and master’s level degrees in chemistry at the University of 
Indonesia and obtained his Ph.D. in organic chemistry with Professor Robert Bates at the University of 
Arizona, followed by postdoctoral study with Professor Bruce Lipshutz in the Department of Chemistry and 
Chemical Biology of the University of California at Santa Barbara. His work at KU, now as Professor of 
Pharmaceutical Chemistry, in the general areas of biotechnology, drug delivery, protein and peptide 
chemistry and biochemistry has been closely allied with that of Ron, who is surely gratified that the work has 
won Teruna admiring notice, as the following recognition attests: PhRMA (Pharmaceutical Research and 
Manufacturers Association) Foundation Award in Excellence in Pharmaceutics, 2014; Research and 
Academic Mentor of the Year, Office for Diversity in Science Training, KU, 2013; Clarence Karcher Lecturer, 
University of Oklahoma, 2005; Fellow of AAPS, 2002; Eurand Honorable Mention Award, Controlled Release 
Society, 2002; Pfizer Research Scholar Award (2002–2004); Self Faculty Scholar, KU (2001–2004). 
 Professor Elizabeth Murphy (Liz) Topp, while ascending the professorial ranks in the Department of 
Pharmaceutical Chemistry at KU, devoted a good part of her research program on peptide and protein 
stability, particularly in amorphous solid states, to collaborations with Ron. She is currently the Dane O. 
Kildsig Chair and Department Head of the Department of Industrial and Physical Pharmacy at Purdue 
University. While still at KU, Liz won the Madison & Lila Self Graduate Mentor Award twice, and was named 
“Teacher of the Year” by AACP. At Purdue, she holds an endowed professorship and won the Seeds for 
Success Award, the AAPS Fellowship, and has been named an Academic Leadership Fellow.  
Global Teacher  
At the very beginning of his professorial career, Ron proved to combine excellence in research with a very 
marked talent for teaching. One ought to note that this combination is not as rare in fact as it may be thought in 
the popular imagination; commonly good teachers are good researchers and bad teachers are bad researchers. 




The phenomenal difference with Ron is that he is not just good at both activities, but he is extraordinarily good 
at both. In 1980, the year after he was promoted to full professor of biochemistry, Ron won the Mortar Board 
Outstanding Educator Award, a student-sponsored award that is given to faculty members for “their dedication 
to KU and positive influence on students both academically and personally.” Most of us feel that when such 
recognition comes directly from students, as is the case here, it is especially significant. His excellence in 
teaching continued throughout his career at KU as evidence by his selection in 1997 to receive the Louis Byrd 
Graduate Educator Award and his selection in 2005 to receive the Chancellors Club Career Teaching Award. The 
Chancellors Club Career Teaching Award is the most prestigious teaching award given to faculty members at KU.  
Ron often managed to combine his talents in teaching and research in very unique and effective ways.  Starting 
in 1994, as he was developing his research program into one (in the Department of Pharmaceutical Chemistry) 
incorporating drug delivery as a main theme, he launched two short courses, one on cell lines and tissue culture 
in pharmaceutical research and development, the other on designing drugs with optimal in-vivo activity after 
oral administration. These courses were given in circumstances, often at meetings of professional associations, 
so that the attendance of academics, students, and professional practitioners could be expected. This led to a 
very effective evangelization of the gospel Ron was promoting. These efforts were continued well into the 21st 
Century. For example, the oral-administration course was given on-site at pharmaceutical firms throughout the 
USA and in Europe (see Characterization of Drug-like Properties section) from 2000-2008. 
University Administrator 
A certain number of us initially sneer at the idea of making administrative contributions until something 
intervenes: we need something badly and a creative administrator steps into the breach, or a good friend 
becomes an active administrator and models how it can be done correctly and usefully. In Ron’s case he must 
have been offered many, many such opportunities at KU. He seems to have tried out only the Directorship of the 
Center for Biomedical Research (7 years), the Chair of Pharmaceutical Chemistry (15 years), and Acting Dean of 
the School of Pharmacy (2 years). Ron says these were “test drives” and that he “chose to dedicate my life to 
teaching, mentoring, and research.” He has certainly had a full life of his chosen emphases, but it is hard to 
conceive of anyone else who would consider a total of 24 years to be a test drive! 
International Graduate Education: GPEN, the Globalization of Pharmaceutics Education Network 
During the 1990s, Ron was as busy at consulting and advisory activities for the pharmaceutical industry as he 
had been nearly all his professional life: since 1975, he consulted for over 80 pharmaceutical companies and 
lectured at over 500 universities, research institutes, and pharmaceutical and biotechnology companies around 
the world. These activities doubtless provided him with a privileged viewpoint from which to observe the effects 
of conversion of large parts of the industry to international firms with movements of persons and information 
from place to place on a gigantic scale, in short the globalization of the industry. As Dean Kenneth Audus, has 
said, “Professor Borchardt recognized that the pharmaceutical sciences, and the industry and academia it 
served, was global. Moreover, students from institutions like KU would be working at and interacting with 
colleagues around the world throughout their careers in the pharmaceutical sciences. Therefore, as part of their 




graduate education, he pursued the idea that students should be exposed to the international science and 
culture of the other top pharmaceutics programs in the world.” 
To see where this idea has gone, the reader should go to http://pharmchem.ku.edu/globalization-
pharmaceutics-education-network-gpen.  There one learns that GPEN, Inc., has conducted biennial meetings 
since 1996 in the United States (GPEN1996, University of Kansas)  in Switzerland (GPEN1998, ETH-Zurich), 
Sweden (GPEN2000, Uppsala University) , United States (GPEN2002, University of Michigan), Japan (GPEN2004, 
Kyoto University), United States (GPEN2006, University of Kansas), Belgium (GPEN2008, KU Leuven),  United 
States (GPEN2010, University of North Carolina), Australia (GPEN2012, Monash University), and Finland 
(GPEN2014, University of Helsinki)). A Board of Directors of which Dean and Professor Ken Audus is Chair 
manages this organization. Of the meetings, Audus says, “GPEN meetings are organized in entirety by graduate 
students of the hosting University.  The meeting format includes a keynote address by a prominent scientist, 
scientific presentations and posters by graduate students, short courses by faculty, and social events that help 
introduce students and faculty attendees to the host country’s culture. GPEN encourages the pharmaceutical 
industry to attend, provides support for participation by all of the 52 member schools, and actively endorses 
research exchanges between and among all of the institutions and their pharmaceutics programs.  Professor 
Borchardt is a visionary in graduate education and training particularly with respect to the global needs of the 
pharmaceutical sciences.” It is through these niche meetings that many graduate students have been able to 
make the necessary links with faculty members and industrial representatives around the globe leading to 
excellent future employment opportunities. 
Sometimes people speak of “an idea whose time has come.” There must be extremely few examples as clear as 
this one. 
Editor of Books and Journals 
It is a cliché to say that science requires absolutely that its results and the ideas that are used for interpreting 
them be made available to one’s colleagues world-wide. Since the 18th century, a more and more complex set 
of means for dissemination of scientific information has developed, currently increasingly emphasizing the 
internet and electronic communication, but by and large in the chemical and biological sciences still tied to the 
printing of journals and books of the traditional kind. It is also expected by authors and demanded by readers 
that the publishers of journals and books will subject the individual units of publication, such as a chapter or a 
paper, to some form of peer review. The more rigorous the peer review, the higher will rise the respect and 
prestige that the journal or book and the enterprise that sees them into print and distribution also will rise. Staff 
members undertake some of this work, but to an enormous extent, volunteers from the ranks of practicing 
scientists donate their time and effort to seeing that we all have the opportunity to publish our work. 
Ron has been an exemplary scientific citizen in this regard. He has at the present time been serving as Editor-in-
Chief of the Journal of Pharmaceutical Sciences for 14 years. Prior to assuming the position of Editor-in-Chief, 
Ron served for 5 years as Associate Editor of the Journal of Pharmaceutical Sciences, 3 years as Associate Editor 
of the Journal of Peptide Science, and 2 years as Biotechnology Editor of the AAPS Journal. 




Ron has also made a particularly significant contribution of a sort that often goes unnoticed i.e. editing of books 
and book series that come to be trusted sources of information. Between 1976 and 2007, he and his co-Editors 
brought out collections of expert reviews in books dealing with the chemistry and biochemistry of Ado-Met 
dependent transmethylations,213-215 drug delivery,216 cell culture and tissue models for assessing drug 
absorption,165,166 characterization of drug-like properties, 197-199and prodrugs.200,201  In addition to editing these 
ten books, Ron has also served as Series Editor for 14 volumes of Pharmaceutical Biotechnology (Plenum Press) 
and 9 volumes of Biotechnology: Pharmaceutical Aspects (AAPS Press). 
Consequential Consultation and Entrepreneurship 
Ron has always found the pharmaceutical industry to have a powerful interest in receiving his advice as a 
consultant (from 1971 through the present, on more than 80 consultantship appointments), and as a member of 
advisory boards (from 1992 through the present, with over 30 appointments). These rosters of firms around the 
world reflect nearly the entirety of what might be called the most highly respected of the “pharma elite”. 
On at least one occasion, Ron has dipped more deeply into the client’s activities than just offering suggestions. 
He was drawn into the work of Proteolix Pharmaceuticals on inhibitors of the 2S-proteasome, a large molecular 
machine of the cell that removes cellular detritus, proteins that are no longer useful and therefore have been 
tagged by ubiquitin to identify them as waste. An inhibitor of the proteasome causes it to cease catalyzing the 
destruction of tagged proteins, and the latter accumulate in the cell to the point that apoptosis or programmed 
cell death occurs. If this occurs sufficiently frequently in tumor cells, the inhibitor should be an anti-cancer 
agent. This proves to be the case with multiple myeloma when the inhibitor is carfilzomib (Kyprolis), a 
Proteolix compound co-invented by Ron and now manufactured and distributed by Amgen, Inc. With the 
discovery of carfilzomib, patients with multiple myeloma now have another treatment option. 
In 1997, Ron collaborated with Professor Valentino Stella, Professor Gunda Georg, Dr. Roger Rajewski and Dr. 
Osborne S. Wong to form ProQuest Pharmaceuticals. ProQuest's core technologies included patented prodrug 
strategies for increasing the cell permeation of therapeutic peptides, which came from Ron's laboratory, and 
patented prodrug strategies for enhancing the solubility of insoluble organic-based drugs, which came from 
Professors Stella's and Georg's laboratories. In 2000, Proquest licensed its lead compound (fospropofol) to 
Guilford Pharmaceuticals for preclinical and clinical development. In 2004, Guilford purchased ProQuest 
Pharmaceuticals outright in order to have full control over the clinical development and commercialization of 
fospropofol. LUSEDRA™ (fospropofol) was approved by the US Food and drug administration in 2008 for 
procedural sedation. 
Ron and Pam Moving Forward 
Ron’s exceptional academic career is balanced by his personal successes, the first being his almost 50-year 
marriage to wife, Pam. He is the first to note that Pam should be given full credit for raising and mentoring their 
three children in Lawrence while he spent much of his time in his office and laboratory at the university or 
traveling nationally and internationally. Not surprising, is that each child is successful in his and her own right. 
Scott, the eldest, is a Managing Director at PricewaterhouseCoopers, LLC, in Boston, MA, where he lives with his 




wife, Julie, and their three children, Noelle, Nick, and Catherine. Paul resides in Lawrence where he works as the 
Tax and Compliance Reporting Officer at the Kansas University Endowment Association. His wife, Susan, who 
helps raise their son, Max, is a learning assistant for KU Athletics and teaches online English courses. Kelly, the 
youngest, has recently moved back to Lawrence after accepting a position as a Nurse Education Specialist with 
Children’s Mercy Hospital in Kansas City, MO. Her husband, Phil, a former graduate student of Professor Richard 
Schowen, is a scientist at Zoetis, Inc. in Kalamazoo, MI. 
Though Ron and Pam have lived in Lawrence, KS, for almost 45 years, they still cheer for the UW sports teams 
and the Green Bay Packers. The couple does have divided allegiances, however, during basketball season, as 
decades-long season ticket holders, they cheer for the KU basketball team, a focus of their winter and spring 
free time. While Pam travels with Ron to his various conferences, their most enjoyable trips are often back 
home to Wisconsin to enjoy their lakeside family cottage, sharing that cottage with family and friends every 
summer. Both also enjoy cultivating their extensive gardens in Lawrence, maintaining a backyard the Lawrence 
Journal-World newspaper called “a whimsical, picturesque, woodland habitat that's an absolute joy to behold” 
in a feature on their gardens.  
The Borchardts also enjoy giving back to the universities that have given them so much. Ron and Pam, as well as 
their children, have all set up scholarships to support others in pursuit of their academic dreams. The Borchardts 
give back to UW through the Ronald T. and Pamela K. Borchardt Scholarships for Pharm. D. students.  At KU, all 
the families contribute to various funds including the Borchardt Family Scholarship for Graduate Study in the 
Beach Center on Disability, the Borchardt Family Tax Scholarship in the School of Business, and the Borchardt 
Family Basic Pharmaceutical Sciences Award and Scholarship in the School of Pharmacy.  
The KU community has always been supportive of Ron’s efforts, and he and his family members have flourished 
because of it. The family currently holds a total of eleven degrees from KU. Ron’s extended family, his 
approximately 170 graduate students, postdoctoral fellows, and visiting scientists, bring him a great deal of 
pride as well.  Ron has said that it is his job to teach his students “not just how to get to the five-yard line” but 
how to score a touchdown.  That so many of them have gone on to score that game-winning touchdown, in 
academia, industry and entrepreneurial pursuits, remains one of his greatest legacies. 
Looking back on his career, Ron says he feels extremely fortunate to have had the opportunity to pursue his 
passion for research and teaching at KU.  Having received direction and mentoring from the forward thinking 
minds of Professors Smissman and Higuchi while at the university, Ron now trusts that his colleagues, many of 
whom studied with him, will continue to provide the stability and direction to keep the Department of 
Pharmaceutical Chemistry and the School of Pharmacy at the university thriving. 
In recognition of Ron’s roles as a teacher, mentor and scientist, KU has created the Ronald T. Borchardt 
Distinguished Professorship in Pharmaceutical Chemistry. Notably, Ron’s former graduate students, postdoctoral 
fellows, colleagues and friends in recognition of his contributions to their lives contributed most of the funding 
for this endowed distinguished professorship. 




Ron is a man of many titles and accolades. However, the best of these may be ahead of him. On August 2, 2015, 
he transitioned into his new position as Distinguished Professor Emeritus of Pharmaceutical Chemistry at KU.  
Despite this new title, he will continue to be professionally active. In addition to maintaining his role as Editor-in-
Chief of the Journal of Pharmaceutical Sciences, Ron will also continue to be involved in the leadership of GPEN, 
and to serve on several Scientific Advisory Boards and to provide consultation to pharmaceutical and 
biotechnology companies world-wide. 
With perhaps some more personal time ahead, many have made suggestions for how Ron should spend that 
time: travel, family visits, landscaping, lake trips, or even as his sister suggests, engaging that creative part of his 
brain to learn a new language. Whatever he pursues in the next phase, we, as his friends, family, academic 
children and colleagues, can say one thing for certain: he will do it his way. 
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